Drugs / Cell Culture-Derived H5N1 Subunit Influenza Vaccine
Cell Culture-Derived H5N1 Subunit Influenza Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00812019 | Nov 2008 → Mar 2009 | influenza | Seqirus | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cell Culture-Derived H5N1 Subunit Influenza Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00812019 ↗ |
| Known as | Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine | “The aim of the present dose ranging study is to evaluate the safety, tolerability and immunogenicity of two doses of twelve different formulations of a Cell Culture-Derived...” NCT00812019 ↗ |
| Modality | Vaccine | “Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59” NCT00812019 ↗ |